27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-tailored bivalent COVID-19 vaccine against newer Omicron sublineages.
- These data, posted on the preprint server bioRxiv, indicate that the companies' bivalent vaccine elicits a greater increase in neutralizing antibody titers than the companies' original COVID-19 vaccine against these emerging Omicron sublineages.
- Related: Pfizer, BioNTech Start Work On Next-Gen COVID-19 Vaccine Candidate For Broader Protection.
- One month after a 30-µg booster (fourth) dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibodies against BA.4.6 increased 11.1-fold, neutralizing antibodies against BA.2.75.2, BQ.1.1, and XBB.1 increased by 6.7-fold, 8.7-fold, and 4.8-fold, respectively.
- By comparison, the neutralizing antibody titers against BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 following the original shot's booster dose increased 2.3-fold, 2.1-fold, 1.8-fold, and 1.5-fold, respectively.
- Overall, the bivalent booster generated a greater increase in neutralizing antibodies against emerging Omicron sublineages than the original Pfizer-BioNTech COVID-19 vaccine.
- Price Action: PFE shares are down 0.08% at $48.29, and BNTX stock is up 0.31% at $166.78 on the last check Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!